FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vachinaton	D C	20540
Vashington,	D.C.	20549

STATEMENT	OF CHANGES I	N BENEFICIAL	OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Khattar Jack A.						2. Issuer Name and Ticker or Trading Symbol SUPERNUS PHARMACEUTICALS, INC. [SUPN]								ck all application	able)	g Person(s) to Issuer 10% Owner		mer	
(Last) (First) (Middle) C/O SUPERNUS PHARMACEUTICALS, INC.,					3. Date of Earliest Transaction (Month/Day/Year) 08/23/2023								X Officer (give title Other (specify below) President, CEO						
9715 KEY WEST AVENUE					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) ROCKVII	LE MC	2	0850)	X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)					Ru	Rule 10b5-1(c) Transaction Indication													
							Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Tabl	e I - Nor	n-Deriv	ative	Sec	curities	Acc	uired,	Dis	posed of	f, or Ber	eficially	/ Owned					
Date					action 2A. Deemed Execution Date, if any (Month/Day/Year)			3. 4. Securities Acquired (A) Transaction Code (Instr. 5) 5)			5. Amoun Securities Beneficia Owned Fo	Form (D) or		: Direct Ir r Indirect B str. 4) C	7. Nature of ndirect Beneficial Ownership				
										v	Amount	(A) or (D)	Price	Reported Transacti (Instr. 3 a	on(s)		(ins	Instr. 4)	
Common Stock												849	849,267		D				
Common Stock											1,038,950			I 1	By the KBT Frust				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	ed Date,	4. Transaction Code (Ins		5. Number of		6. Date Exercisable a Expiration Date (Month/Day/Year)		sable and			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares	mber					
Performance Share Unit	\$0	08/23/2023			A		35,000		(1)		(1)	Common Stock	35,000	\$0	35,00	0	D		

Explanation of Responses:

1. On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period.

/s/ Timothy C. Dec, as attorney-08/25/2023 in-fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.